0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-13 R alpha 2

IL-13 R alpha 2

Brief Information

Name:Interleukin-13 receptor subunit alpha-2
Target Synonym:Interleukin 13 Receptor Alpha 2 Chain,Interleukin-13 Receptor alpha2 Subunit,IL-13RA2,IL-13R-alpha-2,Interleukin-13-binding protein,IL13RA2,Interleukin 13 Receptor Subunit Alpha 2,Interleukin 13 Receptor, Alpha 2,IL-13 Receptor Subunit Alpha-2,Cancer/Testis Antigen 19,IL-13R Subunit Alpha-2,Interleukin-13 Receptor Subunit Alpha-2,Interleukin 13 Binding Protein,CD213a2 Antigen,CD213A2,IL-13R,IL13BP,IL13R,CT19
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IL2-H52H5-BLI
 IL-13 R alpha 2 BLI

Loaded Human IL-13, Fc Tag (Cat. No. IL3-H5256) on Protein A Biosensor, can bind Human IL-13 R alpha 2, His Tag (Cat. No. IL2-H52H5) with an affinity constant of 6.09 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

IL2-H82E6-ELISA
 IL-13 R alpha 2 ELISA

Immobilized Biotinylated Human IL-13 R alpha 2, His,Avitag (Cat. No. IL2-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-IL-13 R alpha 2 Antibody, Mouse IgG1 with a linear range of 0.4-2 ng/mL (QC tested).

Synonym Name

IL13RA2,CD213A2,CT19,IL-13R,IL13BP

Background

Interleukin-13 receptor subunit alpha-2 is also known as IL13Rα2, IL13Ra2 cluster of differentiation 213A2, CD213A2, CT19, IL-13R, IL13BP, and is a membrane bound protein that in humans is encoded by the IL13RA2 gene. IL13Rα2 is closely related to IL13Rα1, a subunit of the interleukin-13 receptor complex. This protein binds IL13 with high affinity, but lacks any significant cytoplasmic domain, and does not appear to function as a signal mediator. It is, however able to regulate the effects of both IL13 and IL4, despite the fact it is unable to bind directly to the latter. It is also reported to play a role in the internalization of IL13. IL13Rα2 is a component of the cell surface receptors, however, the majority exists in intracellular pools and in soluble form, and thus plays an opposite role as a potent IL13 antagonist compared with IL13Rα1. It also functions as an inhibitor of IL4-dependent pathway probably through the physical interaction between the short intracellular domain of and cytoplasmic domain of IL13Rα2 and the IL4Rα chain. In spite of the failed STAT signaling function, IL13Rα2 dose induce TGF-beta production and fibrosis. Additionally, IL13Rα2has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MB-101 (Mustang Bio) MB-101 Phase 1 Clinical Mustang Bio Inc, City Of Hope National Medical Center Glioblastoma; Central Nervous System Neoplasms; Brain Neoplasms Details
IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Medulloblastoma; Ependymoma; Squamous Cell Carcinoma of Head and Neck; Adenoma, Islet Cell; Adenocarcinoma of Lung; Glioblastoma; Adrenocortical Carcinoma; Neuroendocrine Tumors; Uveal melanoma; Breast Neoplasms; Thyroid Neoplasms; Paraganglioma; Melanoma Details
IL13Rα2 targeted CAR-T cell(Yooyoung) YYB-103; CLM-103 Phase 1 Clinical Yooyoung Glioma; Amyotrophic Lateral Sclerosis Details
IL13Rα2 CAR-T cell therapy(TCRCure Biopharma) Phase 1 Clinical Tcrcure Biopharma Ltd Glioma Details
MT-026 MT-026 Phase 1 Clinical T-Maximum Pharmaceutical (Suzhou) Co Ltd Glioma Details
SNC-109 SNC109; SNC-109 Phase 1 Clinical Shanghai Simnova Biotechnology Co Ltd Glioblastoma Details
MB-101 (Mustang Bio) MB-101 Phase 1 Clinical Mustang Bio Inc, City Of Hope National Medical Center Glioblastoma; Central Nervous System Neoplasms; Brain Neoplasms Details
IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Medulloblastoma; Ependymoma; Squamous Cell Carcinoma of Head and Neck; Adenoma, Islet Cell; Adenocarcinoma of Lung; Glioblastoma; Adrenocortical Carcinoma; Neuroendocrine Tumors; Uveal melanoma; Breast Neoplasms; Thyroid Neoplasms; Paraganglioma; Melanoma Details
IL13Rα2 targeted CAR-T cell(Yooyoung) YYB-103; CLM-103 Phase 1 Clinical Yooyoung Glioma; Amyotrophic Lateral Sclerosis Details
IL13Rα2 CAR-T cell therapy(TCRCure Biopharma) Phase 1 Clinical Tcrcure Biopharma Ltd Glioma Details
MT-026 MT-026 Phase 1 Clinical T-Maximum Pharmaceutical (Suzhou) Co Ltd Glioma Details
SNC-109 SNC109; SNC-109 Phase 1 Clinical Shanghai Simnova Biotechnology Co Ltd Glioblastoma Details

This web search service is supported by Google Inc.

totop

Laisser un message